Literature DB >> 19527483

Adiponectin decreases pyruvate dehydrogenase kinase 4 gene expression in obese- and diabetic-derived myotubes.

A J McAinch1, D Cameron-Smith.   

Abstract

AIM: To investigate the effects of globular adiponectin (gAd) on gene expression and whether these effects are mediated through 3',5'-cyclic monophosphate-activated protein kinase in skeletal muscle myotubes obtained from lean, obese and obese diabetic individuals.
METHODS: Rectus abdominus muscle biopsies were obtained from surgical patients to establish primary skeletal muscle cell cultures. Three distinct primary cell culture groups were established (lean, obese and obese diabetic; n = 7 in each group). Once differentiated, these cultures were then exposed to gAd or 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (AICAR) for 6 h.
RESULTS: Stimulation with gAd decreased pyruvate dehydrogenase kinase 4 (PDK4) gene expression in the obese and diabetic samples (p < or = 0.05) and increased cytochrome c oxidase (COX) subunit 4 (COXIV) gene expression in the myotubes derived from lean individuals only (p < 0.05). AICAR treatment also decreased PDK4 gene expression in the obese- and diabetic-derived myotubes (p < or = 0.05) and increased the gene expression of the mitochondrial gene, COXIII, in the lean-derived samples only (p < 0.05).
CONCLUSIONS: This study demonstrated distinct disparity between myotubes derived from lean compared with obese and obese diabetic individuals following gAd and AICAR treatment. Further understanding of the regulation of PDK4 in obese and diabetic skeletal muscle and its interaction with adiponectin signalling is required as this appears to be an important early molecular event in these disease states that may improve blood glucose control and metabolic flux.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19527483     DOI: 10.1111/j.1463-1326.2009.01042.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  5 in total

1.  Diurnal Variation in PDK4 Expression Is Associated With Plasma Free Fatty Acid Availability in People.

Authors:  Shintaro Yamaguchi; Anna C Moseley; Paloma Almeda-Valdes; Kelly L Stromsdorfer; Michael P Franczyk; Adewole L Okunade; Bruce W Patterson; Samuel Klein; Jun Yoshino
Journal:  J Clin Endocrinol Metab       Date:  2018-03-01       Impact factor: 5.958

2.  Diisopropylamine dichloroacetate, a novel pyruvate dehydrogenase kinase 4 inhibitor, as a potential therapeutic agent for metabolic disorders and multiorgan failure in severe influenza.

Authors:  Kazuhiko Yamane; Irene L Indalao; Junji Chida; Yoshikazu Yamamoto; Masaaki Hanawa; Hiroshi Kido
Journal:  PLoS One       Date:  2014-05-27       Impact factor: 3.240

3.  CB1 Ligand AM251 Induces Weight Loss and Fat Reduction in Addition to Increased Systemic Inflammation in Diet-Induced Obesity.

Authors:  Lannie O'Keefe; Teresa Vu; Anna C Simcocks; Kayte A Jenkin; Michael L Mathai; Deanne H Hryciw; Dana S Hutchinson; Andrew J McAinch
Journal:  Int J Mol Sci       Date:  2022-09-28       Impact factor: 6.208

4.  Transcriptional regulation of pyruvate dehydrogenase kinase.

Authors:  Ji Yun Jeong; Nam Ho Jeoung; Keun-Gyu Park; In-Kyu Lee
Journal:  Diabetes Metab J       Date:  2012-10-18       Impact factor: 5.376

5.  Genetic inactivation of pyruvate dehydrogenase kinases improves hepatic insulin resistance induced diabetes.

Authors:  Rongya Tao; Xiwen Xiong; Robert A Harris; Morris F White; Xiaocheng C Dong
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.